Primary Pulmonary Hypertension

Detailing state-of-the-art developments in the various aspects of primary pulmonary hypertension (PPH), this practical reference explores the history, most current scientific concepts, and treatments of this disease. Includes new advances not yet formally published! Written by nearly 30 of the top international experts in the field, Primary Pulmonary Hypertension addresses the general histological features of the normal and hypertensive pulmonary vasculature and the pathology of PPH discusses etiological possibilities of pathogenesis, common morphological features, and findings in experimental models examines risks factors for PPH and looks separately at familial PPH and PPH in children presents an approach to the differential diagnosis of pulmonary hypertension, emphasizing the recognition of PPH elucidates the invasive and noninvasive modalities available for obtaining qualitative and quantitative hemodynamic data for the diagnosis of PPH covers a variety of therapeutic options and much more!

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

​This title will be presented as highly practical information on pharmaceutical options in pulmonary hypertension, written in a quick-access, no-nonsense format. The emphasis will be on a just-the-facts clinical approach, heavy on tabular material, light on dense prose. The involvement of the ISCP will ensure that the best quality contributors will be involved and establish a consistent approach to each topic in the series. Each volume is designed to be between 100 and 150 pages containing practical illustrations and designed to improve understand and practical usage of cardiovascular drugs in specific clinical areas.​

This open access book focuses on the molecular mechanism of congenital heart disease and pulmonary hypertension, offering new insights into the development of pulmonary circulation and the ductus arteriosus. It describes in detail the molecular mechanisms involved in the development and morphogenesis of the heart, lungs and ductus arteriosus, covering a range of topics such as gene functions, growth factors, transcription factors and cellular interactions, as well as stem cell engineering technologies. The book also presents recent advances in our understanding of the molecular mechanism of lung development, pulmonary hypertension and molecular regulation of the ductus arteriosus. As such, it is an ideal resource for physicians, scientists and investigators interested in the latest findings on the origins of congenital heart disease and potential future therapies involving pulmonary circulation/hypertension and the ductus arteriosus.

The heart and lung are intricately linked. When the heart is affected by disease, the lungs will often show some related pathological or clinical conditions and vice versa. Pulmonary heart disease is by definition a condition when the lungs cause the heart to fail. The left ventricle in combination with the other structures in the “left heart” pumps blood throughout the body. The right ventricle (and structures of the “right heart”) pumps blood to the lungs where it is oxygenated and returned to the left heart for distribution. In normal circumstances, the right heart pumps blood into the lungs without any resistance. The lungs usually have minimal pressure and the right heart easily pumps blood through. However when there is lung disease present, like emphysema, chronic obstructive lung disease (COPD) or pulmonary hypertension- the small blood vessels become very stiff and rigid. The right ventricle is no longer able to push blood into the lungs and eventually fails. This is known as pulmonary heart disease. Pulmonary heart disease is also known as right heart failure or cor pulmonale. The chief cause of right heart failure is the increase in blood pressure in the lungs (pulmonary artery).

Pulmonary hypertension is a world�wide problem which is gaining greater attention and is more frequently diagnosed now, more than the past ten or twenty years, because of the use and interpretation of echocardiograms. Pulmonary Hypertension raises questions and discusses concepts which will address the issue of etiology of pulmonary hypertension, its pathobiology with its close proximity to cancer, and the consequences of severe PH which is right heart failure and death.